Friday 6 November 2026 Export WST’s income statement to Excel — free account

West Pharmaceutical Services, Inc.

WST Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.

Revenue: +8.69%
EPS: +56.7%
Free cash flow: +12.3%
Total debt: +0.10%

Quarter to September 2026, against a year earlier

392.97 15.81 −3.87%

Follow WST

Alert me

Market cap: $27.3B
P/E: 43.8×
Fwd P/E: 48.1×
Dividend yield: 0.22%
F-score: 8/9
Altman Z: 13.89
Beneish M: −2.79
Dividend safety: 100/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

West Pharmaceutical Services, Inc. (WST) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, West Pharmaceutical Services, Inc. (WST) trades at a price to free cash flow of 61.5×. Over the past ten years it has ranged from 35.9× (February 2026) to 137× (January 2017); the current reading is higher than 50% of that period. That is above the Medical Instruments & Supplies industry median of 23.5× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/WST/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="West Pharmaceutical Services, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/WST/metrics/price-to-free-cash-flow">West Pharmaceutical Services, Inc. (WST) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	42.8×	(51.24%)
FY2024	87.7×	39.05%
FY2023	63.1×	57.56%
FY2022	40.0×	(62.50%)
FY2021	107×	50.09%
FY2020	71.1×	53.42%
FY2019	46.4×	16.24%
FY2018	39.9×	(29.36%)
FY2017	56.5×	(57.02%)
FY2016	131×	137.89%

Period	Price to free cash flow	Change
Sep 2026	58.1×	(1.08%)
Jun 2026	58.7×	47.71%
Mar 2026	39.7×	(7.11%)
Dec 2025	42.8×	(15.25%)
43 more quarters	Free account

Against its own ten years

Low 35.9× High 137×

Ten-year median 61.5×

Current reading's percentile 50

Company	Price to free cash flow
SOLV Solventum Corporation compare	n/m
MDLN Medline Inc. compare	11.3×
BAX Baxter International Inc. compare	11.6×
ALGN Align Technology, Inc. compare	16.8×
COO The Cooper Companies, Inc. compare	18.1×
BDX Becton, Dickinson and Company compare	18.3×
RMD ResMed Inc. compare	21.5×
ALC Alcon compare	23.3×
WST West Pharmaceutical Services, Inc.	61.5×
Medical Instruments & Supplies industry median	23.5×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

West Pharmaceutical Services, Inc. (WST) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on WST

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on WST

Stockrow Weekly